Immunosuppression in kidney transplant recipients with decreased graft function and severe histological vascular changes can be particularly challenging. Belatacept could be a valuable option, as a rescue therapy in this context. We report a retrospective case control study comparing a CNI to belatacept switch in 17 patients with vascular damage and low eGFR to a control group of 18 matched patients with CNI continuation. Belatacept switch was performed on average 51.5 months after kidney transplantation (6.2-198 months). There was no difference between the two groups regarding eGFR at inclusion, and 3 months before inclusion. In the "CNI to belatacept switch group," mean eGFR increased significantly from 23.5 AE 6.7 mL/min/1.73m 2 on day 0, to 30.4 AE 9.1 mL/min/1.73 m 2 on month 6 (p < 0.001) compared to the control group, in which no improvement was observed. These results were still significant on month 12. Two patients experienced biopsy-proven acute rejection. One was effectively treated without belatacept discontinuation. Two patients needed belatacept discontinuation for infection. In conclusion, the remplacement of CNI with belatacept in patients with decreased allograft function and vascular lesions is associated with an improvement in eGFR.
Introduction
The inclusion of calcineurin inhibitors (CNI) in immunosuppressant regimens has significantly improved early kidney allograft survival (1) (2) (3) . Paradoxically, strategies based on CNI have not been associated with an improvement in long-term graft survival. Importantly, CNI are the cause of multiple metabolic complications (new-onset diabetes, hypertension, dyslipidemia) (4), while the population of kidney transplant recipients with a high vascular risk has sharply increased over the last decade.
The BENEFIT study, reported by Vincenti et al (4) , demonstrates an improved estimated glomerular filtration rate (eGFR) and patient and graft survival in belatacepttreated kidney transplant recipients, in comparison to cyclosporine as a first line immunosuppression strategy. Although the long-term difference in eGFR shown in this study is assumed to be a consequence of cyclosporineinduced vascular and tubulo-interstitial fibrosis (5), renal vasoconstriction due to cyclosporine may be a major short-and long-term contributor to this beneficial effect (6) . Replacing CNI with belatacept may therefore be of specific interest in patients with allograft vascular lesions and precarious function. Despite the negative results of the BENEFIT-Extended Criteria Donors (BENEFIT-EXT) trial on patient and graft survival (7) , hemodynamic factors should be taken into account in this particular context. On this pathophysiological background we performed a CNI to belatacept switch in kidney allograft recipients with decreased graft function associated with predominant vascular lesions on allograft biopsy, in order to limit the vascular and hemodynamic toxicity of CNI (8) . To date, no study has analyzed the short-and long-term consequences of belatacept as an alternative to CNI in patients with decreased kidney function associated with predominant vascular lesions on allograft biopsy.
conversion was performed as a rescue therapy at least 6 months after renal transplantation.
Patients and Methods

Study design: flow charts and patients
In Rouen University Hospital transplantation unit, 58 patients had a CNI to belatacept switch between October 2013 and July 2016. Belatacept indication was systematically decided during a medical meeting, after discussion of potential therapeutic alternatives. All the patients were EBV seropositive before the switch. Transplant biopsies were obtained before conversion and scored according to the Banff classification (9,10) by a single experienced pathologist.
The patients who fulfilled the following eligibility criteria were included in the "CNI to belatacept switch group" of the present study:
1 A CNI to belatacept switch performed after 6 months following kidney transplantation 2 Patients who underwent a kidney graft biopsy before the switch 3 Histological features associating: a A chronic vascular score (CV) ≥ CV2 b And the sum of interstitial inflammation (i) and tubulitis (t) scores (i + t) ≤1 c And the sum of glomerulitis (g) and peritubular capillaritis (ptc) score (g + ptc) ≤2 and chronic glomerulopathy (cg) ≤1 4 A follow-up >6 months under belatacept and after kidney graft biopsy This group was compared to a historical cohort including kidney transplant recipients who continued after the graft biopsy ("control group") and fulfilled the following eligibility criteria (this group was built with our local kidney allograft biopsies database [ Figure 1] 
Treatment
In the CNI to belatacept switch group, 5 mg/kg belatacept was administered intravenously on days 1, 15, 29, 43, 57, and then 28 days thereafter as published for late stage conversion (13) Cyclosporine or tacrolimus was tapered as follows: 100% on day 1, 50% on day 2, 25% on day 15, and 0 from day 29 onwards. Other immunosuppressive medications, including or corticosteroids, were maintained at existing doses unless modification was necessary.
In the control group, cyclosporine, tacrolimus was continued after graft biopsy, along with other immunosuppressive medications.
Outcomes
We evaluated kidney graft function by eGFR (MDRD) (11) biopsy for the control group and date of belatacept switch for the CNI to belatacept switch group), 6 months after inclusion (M6) and 1 year (M12) after inclusion.
The primary endpoint was the difference in eGFR variation from baseline to month 6 and from baseline to month 12 between the 2 groups.
LDL cholesterol, Proteinuria/creatininuria ratio (P/C ratio) and HbA1c for diabetic patients were compared between each group, on D0 and M12.
The safety profile was also reported in the CNI to belatacept switch group, including biopsy-confirmed acute rejection (AR), infectious complications and death.
Statistical methods
Quantitative data were presented as mean (SD), or median (range) when data were not normally distributed. Qualitative data were presented as percentages. The non-parametric Wilcoxon (quantitative data) and Mann-Whitney test (qualitative data) were used to compare baseline characteristics and mean eGFR observed during the follow up in the two groups.
All analyses were performed using StatView version 5.0 (SAS Institute, Cary, NC).
Results
Patients
Between October 2013 and July 2016, 17 patients were eligible to be included in the CNI to belatacept switch group. The switch was performed on average 51.5 months after kidney transplantation (6.2-198 months) with a median interval of 2.3 months between biopsy and conversion. We included 18 patients in the control group ( Figure 1 ). Baseline characteristics of these patients are reported in Table 1 and the histological features of graft biopsies in Table 2 . There was no statistical difference between these two groups at time of inclusion (D0 The major part of the patients switched were primary transplants and non sensitized as compared with the CNI group. Nevertheless in the belatacept group, 2 patients experienced humoral rejection treated before the swicth with positive DSA with highly suspected inadherence.
Descriptive data
The median duration of the follow-up was 23.9 months (6.3;47.0(and 31.9 months (7.2;70.1) in CNI to belatacept switch and control group, respectively. At the latest follow-up, 16/17 patients included in the CNI to belatacept switch group (one patient had a mixed cellular and humoral rejection 4 months after the switch requiring belatacept discontinuation) and 18/18 in the control group could be evaluated at 6 and 12 months. In this group, CNI through levels (C0) were significatively lower at M6 (C0 ciclosporine at M6: 80 ng/mL versus 109 ng/mL at D0; C0 tacrolimus 4.7 ng/mL at M6 versus 6.1 ng/mL at D0; p = 0.03).
Outcome data, main results Evaluation 6 and 12 months after inclusion: There was no difference between the two groups regarding eGFR at inclusion and 3 months before inclusion (p = 0.06 and p = 0.32). After 6 months patients included in the CNI to belatacept switch group significantly improved graft function from baseline (mean ; p = 0.11). After 12 months, patients in the belatacept group had still significantly higher eGFR than in the control group (30.0 AE 9.7 mL/min/1.73 m2 versus 24.7 AE 6.7 mL/min/1.73 m2; p = 0.01) (Figure 2 and Table 3 ).
Six patients reached at least 2-years follow-up after belatacept switch, and demonstrated a persistent improvement in eGFR (eGFR 24.6 AE 5.9 mL/min/1.73 m² at day 0, 30.2 AE 6.2 mL/min/1.73 m² at M6, 30.5 AE 5.2 mL/ min/1.73 m² at M12 and 33.0 AE 6.3 mL/min/1.73 m² at M24).
There was no difference between patients converted sooner. Mean change in eGFR was 6.3 mL/min/1.73 m² for conversion performed earlier than 24 months after transplantation, compared to 6.8 mL/min/1.73 m² if the switch was performed after.
For kidney graft with KDPI ≥ 85%, belatacept switch was more effective without regards to the timing of the switch. For KDPI ≥85%, mean eGFR at D0 was 24.5 AE 5.7 mL/min/1.73 m2; mean eGFR at M6 was 34.6 AE 6.8 mL/min/1.73 m2 and mean eGFR at M12 was 34.4 AE 6.1 mL/min/1.73 m2. For KDPI <85%, the improvement was less important: mean eGFR at D0: 21.7 AE 7.9 mL/min/1.73 m 2; mean eGFR at M6: 26.2 AE 9.3 mL/min/1.73 m 2 ; mean eGFR at M12: 25.4 AE 11.0 mL/min/1.73 m2 (Figure 3 ). LDL cholesterol, P/C ratio, and HbA1c: In the belatacept group, mean LDL cholesterol was 2.53 AE 1.00 mmol/L at day 0 and 2.35 AE 0.98 mmol/L at M12 compared to 2.11 AE 0.74 mmol/L at day 0 and 2.24 AE 0.68 mmol/L at M12 in the CNI group (p = NS). In the belatacept group mean P/C ratio was 0.78 AE 0.61 g/g at day 0 and 0.49 AE 0.48 g/g at M12 compared to 0.71 AE 0.68 g/g at day 0 and 1.00 AE 1.10 g/g at M12 in the CNI group (p = NS).
There were 6 diabetic patients in the belatacept group and 7 in the control group: in the belatacept group, mean HbA1c was at 7.46 AE 1.70 at day 0 and 7.12 AE 0.97 at M12 compared to 6.88 AE 1.51 at day 0 and 7.46 AE 0.92 at M12 in the CNI group (p = NS).
Safety: Two patients experienced biopsy-proven acute rejection. The first patient demonstrated 2 months after belatacept switch a grade IIb T cell mediated rejection effectively treated with steroid pulse, without belatacept discontinuation. The other patient had a mixed cellular and humoral rejection 4 months after the switch requiring 
CNI, calcineurin inhibitor belatacept discontinuation, and leading to graft loss 18 months after.
Two patients had belatacept discontinuation for infectious reason. The first patient 16 months after the switch, because of a varicella zoster virus (VZV) vasculitis. She died 2 months after discontinuation. A pneumocystis pneumonia was diagnosed in the second patient 17 months after the switch leading to belatacept discontinuation and graft loss 6 months after discontinuation.
Discussion
This case control study compared two immunosuppressive strategies after a kidney graft biopsy performed in kidney transplant recipients with decreased eGFR and severe chronic vascular damage. To our knowledge, this is the first study to evaluate a rescue strategy with belatacept in such a homogenous population with this specific presentation. Conversion to belatacept was significantly associated with an improvement in eGFR (mean 7 mL/min), while CNI continuation or minimization was not.
Quality of life impairment, morbidity, mortality, and costs associated with dialysis place graft preservation strategies in the foreground (14) . Patients in this study were approaching the need to return to dialysis (mean eGFR at conversion, 23.5 mL/min) and the timing of conversion was quite late (mean 51.5 months post transplant). Even if the follow up and the number of patients included are not sufficient to draw definitive conclusions on graft survival, the results of this study suggest that the use of belatacept as a rescue strategy could be an alternative to delay dialysis requirement and to extend kidney graft lifetime.
Currently, no conversion scheme has been shown to benefit patients with ageing and vascular allograft who have been exposed to long-term immunosuppression with CNI and who exhibit declining graft function. In the late-stage setting, patients with poor renal function have been shown to experience limited benefit from mTORi conversion, due to an increased incidence of adverse events (15) (16) (17) . CNI withdrawal without replacement is generally not a valuable option (3). CNI minimization, as was performed here in the control group, has not proven strong evidence of graft function improvement, while it can increase the risk of de novo DSA appearance and chronic humoral rejection (18) . As was reported in the princeps study, belatacept seems to minimize the risk of de novo DSA appearance. Moreover in these patients who are frequently at high cardiovascular risk, belatacept conversion can improve blood pressure, diabetes mellitus and dyslipidemia (19) . In our study, regarding LDL cholesterol, P/C ratio and HbA1c, a marginal improvement was observed in the belatacept group, but the differences did not reach statistical significance.
In the phase II study published in 2011 by Rostaing et al, CNI switch to belatacept was also associated with eGFR improvement (13) . This improvement was also found at 3 years, as was recently reported by Grinyo et al (20) . Nevertheless, the switch was performed in patients with stable renal function and not as a rescue therapy. One
French study published by Le Meur et al evaluated the efficacity of a CNI to belatacept switch performed because of CNI intolerance. In contrast with the present work, this study specifically addressed an early switch strategy in renal recipients of grafts derived from extended criteria donors (21 DSA. We found the same improvement between D0 and M6, and M12 in our study. Nevertheless, the patients presented in Brakemeier's study are relatively heterogenous, mostly regarding histology: 33.8% were cv0 or cv1, while the other patients were cv2 or cv3 according Banff classification. In addition, the control group was not comparable in terms of histological lesions. It is therefore difficult to conclude from this study regarding a potential superiority of belatacept switch as compared to continuing CNI or switching to mtor inhibitors. This issue was specifically addressed in our study. As a consequence, the results of the present study are limited to this specific population of patients with decreased kidney function and severe chronic vascular lesions.
An interesting result is that for kidney grafts with KDPI ≥85%, belatacept switch seems to be more effective regardless of the timing of the switch. We speculate than in this subset of grafts, vascular lesions are a consequence of the comorbidities of the donor, rather than secondary to immune-mediated lesions or CNI toxicity. In this very particular situation (KDPI 85% and cv2 or 3 on graft biopsy), we believe CNI should not be considered as a first-line option and belatacept may probably increase life expectancy of the kidney allograft. This point, and the improvement of patient survival, have to be confirmed with additional studies (7).
For the safety concerns, it is difficult to draw solid conclusions from our study. We observed 2 cases of rejection, of which one recovered completely after treatment, allowing belatacept continuation. As in previous studies, the acute rejection occurred soon after initiating belatacept (4, 7, 20) . The rate of AR in the phase II study (13) was 7.1% after 1 year (all cases resolved with treatment) and less than 10% after 3 years (20) . We reported 2 very serious infectious adverse events, and in one case the patient died from a very rare cerebral VZV complication. The rate of acute viral infections in Brakemeier' s study (22) was higher than in the phase II study (13) (22.8% vs. 13.3%), in probably more stable patients. We should be cautious and informed about this kind of adverse events, but larger cohorts are required to evaluate the risks of belatacept used as a rescue strategy.
In conclusion, in the present study, the replacement of CNI with belatacept in patients with decreased allograft function and vascular histological lesions is associated with an improvement in eGFR. In this specific context, these results suggest that belatacept may afford prolonged graft survival, and a delay in the time for dialysis.
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